IL1RL2 and systemic lupus erythematosus: The IL-36 receptor inhibitor, spesolimab, achieves remission in adults with refractory GPP/SLE cases after conventional therapy failure (29), with preliminary pediatric data on GPP showing favorable outcomes (40).